- Home
- ACAA vs PROK Comparison
ACAA vs PROK Comparison
Compare ACAA & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACAA | PROK |
|---|---|---|
| Founded | 2025 | 2015 |
| Country | United States | United States |
| Employees | N/A | 231 |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.6M | 359.4M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACAA | PROK |
|---|---|---|
| Price | $10.02 | $1.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 55.4K | ★ 1.3M |
| Earning Date | N/A | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $9.91 | $1.30 |
| 52 Week High | $10.24 | $3.48 |
Technical Indicators
Market Signals| Indicator | ACAA | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 53.86 | 43.55 |
| Support Level | $9.96 | $1.56 |
| Resistance Level | $10.24 | $2.01 |
| Average True Range (ATR) | 0.01 | 0.12 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 66.67 | 17.05 |
Price Performance
Historical ComparisonAbout ACAA Averin Capital Acquisition Corp. Class A Ordinary Shares
Averin Capital Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.